Deciphera Pharmaceuticals (DCPH) to Offer $250M in Stock

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) announced the commencement of a registered underwritten public offering of $250.0 million in shares of its common stock. In addition, Deciphera intends to grant the underwriters a 30-day option to purchase up to $37.5 million in shares of its common stock.

J.P. Morgan, Piper Sandler and Jefferies are acting as joint book-running managers for the offering. Guggenheim Securities is acting as lead manager for the offering. SunTrust Robinson Humphrey is acting as co-manager for the offering.

Deciphera intends to use the net proceeds from the offering to fund general corporate purposes, which may include research and development and clinical development costs to support the advancement of its drug candidates, including the continued growth of its commercial and medical affairs capabilities to support its transition from a development-stage company toward a commercial-stage company; the conduct of clinical trials and preclinical research and development activities; working capital; capital expenditures; general and administrative expenses; and other general corporate purposes.

You May Also Be Interested In

• Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
• Tango Therapeutics Inc. (TNGX) PT Raised to $35 at Guggenheim
• Silence Therapeutics launches $150 million ADS public offering